EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent dis + 4️⃣ Exclude drivers like comorbidities & psychosocial factors 🔺️Exclude failure due to Side Effets/CI #EULAR2025 @RheumNow https://t.co/ULD2Xe6p6A

• https://x.com/Nellziade/status/1933828120173326821/photo/1

APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3

• https://x.com/DrMiniDey/status/1933831530633162911/photo/1

Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z

• https://x.com/AdelaCastro222/status/1933834754052247622/photo/1

✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1
• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1
• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1

Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis. Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis #EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq

• https://x.com/drdavidliew/status/1933837278289211854/photo/1

Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt

• https://x.com/bella_mehta/status/1933839837376766180/photo/1

In the APEX Phase 3b RCT (N=1020), guselkumab (IL-23p19 inhibitor) significantly reduced radiographic progression (ΔvdH-S 0.55 & 0.54 vs 1.35 PBO; p≤0.002) and improved ACR20 (67–68% vs 47%) at W24 in biologic-naïve PsA. Safety consistent with prior data. Abstract LB0010 https://t.co/mFDsBsCg6m

• https://x.com/synovialjoints/status/1933843347979800810/photo/1

In 4,121 SpA pts (mean age 45y; 61% male), composite scores w/ joint counts (DAPSA, DAS28, DAS44) best discriminated peripheral arthritis activity vs PGA & SJC alone. All scores had excellent construct validity; CRP weakest. Composite indices may optimize SpA assessment. https://t.co/oM97BEkkH5

• https://x.com/synovialjoints/status/1933598772090843637/photo/1

In clinical practice, not all US enthesitis findings are SpA-specific. Enthesophytes/calcifications common in healthy pts. Inflammatory lesions (PD signal, erosions) at Achilles, distal patella & greater trochanter better distinguish PsA/axSpA. Target key sites to improve US https://t.co/jO61QjKfQp

• https://x.com/synovialjoints/status/1933602240897691962/photo/1

In 581 PsA pts (EuroSpA), MRI showed axial SpA features in 31%: BME (69%), erosions (68%), fat lesions (58%). MRI-axPsA pts: younger (41y vs 46y), male (70%), HLA-B27+ (55%), ↑CRP (13 vs 7 mg/L). Radiographs identified sacroiliitis in 29%. MRI adds key detection. POS0297 https://t.co/nAw0BDAH22

• https://x.com/synovialjoints/status/1933603978006475090/photo/1

Using high-resolution peripheral quantitative computed tomography (HR-pQCT), patients with psoriatic arthritis (PsA) & psoriasis (PsO) show reduced cortical volumetric bone mineral density (vBMD) & thinner cortex vs controls. Bone mechanics impaired: reduced stiffness & failure https://t.co/ghH2cwOYJc

• https://x.com/synovialjoints/status/1933605497426620781/photo/1
• https://x.com/synovialjoints/status/1933605497426620781/photo/1

In real-world PsA, IL-23 inhibitors (guselkumab/risankizumab) showed clinical response in axial/mixed PsA. Best response seen in pts meeting ASAS axial SpA criteria (RR 7.64) & baseline ASDAS-CRP >2.1. Supports role of patient stratification in axial PsA. Abstract#POS0113 https://t.co/qowZZmJOpM

• https://x.com/synovialjoints/status/1933528974468272315/photo/1

Are we missing axial/SIJ lesions in PsA or are we misdiagnosing AxSPA + PSO pts for PsA? 5 register studies including 580+ pts w/ PsA/AxSPA+PSO 1/3 PsA routine care patients had SIJ MRI = SPA 29% Rx SII r-mNY criteria+ of which 38% MRI lesions AxSPA @RheumNow #EULAR2025 https://t.co/DJljlm7T9m

• https://x.com/AurelieRheumo/status/1933516733152641267/photo/1

Depression and anxiety in PsA is higher and has more consequences than in general population Swedish and Danish clinical registers 23000+ PsA pts HR 1.4 specialised psychiatric out/ inpatient care vs. general pop HR for psychiatric in patient care numerically higher but ns. No https://t.co/qduMcwGK0S

• https://x.com/AurelieRheumo/status/1933517944329302271/photo/1